Page 168 - Genentech News Today

Nearly half of 757 relapsing MS patients given Ocrevus early in disease course had no evidence of disease activity 9 years out, study finds.

Operator: Good day, and welcome to the Alexandria Real Estate Equities First Quarter 2023 Conference Call. All participants will be in listen-only mode.

/PRNewswire/ -- DelveInsights Glioma Market Insights report includes a comprehensive understanding of current treatment practices, glioma emerging drugs,...

At ARVO 2023, David Tabano, PhD, discussed the analysis of the largest real-world evaluation of treatment patterns and outcomes in DME patients treated with faricimab.

Walk MS: Chicago hosts annual charity walk at Soldier Field to raise awareness and funds to fight multiple sclerosis.

This meta-analysis pools data from 7 randomized trials to estimate the association between administration of corticosteroids vs usual care or placebo and all-ca

German scientific journal EMBO has issued a correction to a 2008 brain study co-authored by Stanford president Marc Tessier-Lavigne when he worked at Genentech.

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimer's disease (AD)

Ivy Energy’s split value DER billing software earns top recognition for Grid Optimization Innovation in the Critical Human Infrastructure category

The CEOs of Genentech and Amgen protest the latest legislation on drug pricing—one labeling it the “Innovation Reduction Act”